Fuente: International Business Times
Mukesh Kumar Mukesh Kumar's career reflects a consistent focus on a problem that, according to him, continues to limit the pharmaceutical industry's progress: the gap between scientific discovery and patient access. Across more than two decades in drug development and regulatory strategy, he has worked at the intersection of science, commercialization, and compliance, translating complex therapeutic concepts into pathways that can survive the demands of real-world execution. That trajectory now converges in his role as CEO of FDAMap, a company built to guide therapies through what he describes as the most consequential phase of development, the transition from laboratory concept to clinical reality.
